Pavlina P.
- Country
- Bulgaria
- Department
- NA
Research Overview
- Efficacy and Safety of MK-2060 in Preventing Arteriovenous Graft Thrombosis in End-Stage Renal Disease Patients Undergoing Hemodialysis
- Efficacy and Safety of Efepoetin Alfa Versus Darbepoetin Alfa in Anemia Management for Chronic Kidney Disease Patients on Dialysis
- A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
Data & Insights
Has run more than one trial at 23 of 213 partner sites.
Specializations
Cardiovascular disease and heart failure
Clinical research activity includes heart failure, atherosclerotic cardiovascular disease, atrial fibrillation, hypertension, and prevention of major cardiovascular events. The portfolio also covers acute myocardial infarction, high cardiovascular risk, and heart failure with preserved or mildly reduced ejection fraction.
- Heart failure and cardiorenal risk
- Atrial fibrillation and stroke prevention
- Acute myocardial infarction
- Hypertension and vascular risk reduction
Work in this area is linked to cardiovascular innovation across treatment strategies for cardiorenal disease, myocardial ischemia, and long-term prevention of adverse cardiovascular outcomes.
Rheumatology and autoimmune disease
The investigator is involved in studies of psoriatic arthritis, axial spondyloarthritis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, and giant cell arteritis. This therapeutic focus also extends to active psoriatic arthritis and moderate-to-severe autoimmune inflammation.
- Psoriatic arthritis
- Axial spondyloarthritis
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Giant cell arteritis
Research activity in this domain reflects sustained involvement in immune-mediated musculoskeletal and systemic inflammatory conditions.
Nephrology and dialysis-related care
Clinical trial involvement includes chronic kidney disease on hemodialysis, end-stage kidney disease, anemia in dialysis, and prevention of arteriovenous graft thrombosis. The research landscape also touches on kidney impairment in patients with heart failure.
- Hemodialysis and end-stage kidney disease
- Anemia in chronic kidney disease
- Arteriovenous graft thrombosis prevention
- Cardiorenal complications
This area is supported by activity at a dedicated dialysis center and reflects interest in therapies for renal complications and dialysis-associated vascular risk.
Respiratory disease and chronic obstructive pulmonary disease
The investigator is active in chronic obstructive pulmonary disease research, with attention to symptom control, exacerbation reduction, and lung function outcomes. This area represents a focused therapeutic interest in chronic respiratory disease management.
- Chronic obstructive pulmonary disease
- COPD exacerbation prevention
- Airflow limitation
Research in this domain contributes to the development of new options for patients with persistent respiratory symptoms and inflammatory airway disease.
Bone health, metabolic disease, and oncology
Additional clinical interests include postmenopausal osteoporosis, severe hypertriglyceridemia, and non-muscle invasive bladder cancer. These studies broaden the therapeutic scope across skeletal fragility, lipid disorders, and localized uro-oncology.
- Postmenopausal osteoporosis
- Severe hypertriglyceridemia
- Non-muscle invasive bladder cancer
The portfolio also includes interest in bone mineral density, acute pancreatitis risk, and bladder cancer control in early-stage disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.